aclidinium vs umeclidinium
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of aclidinium and umeclidinium. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Tudorza Pressair
Incruse Ellipta
No summary available.
Incruse Ellipta is a medicine that helps people with COPD breathe easier. It contains umeclidinium, which is a long-acting muscarinic antagonist (LAMA).
Information not available.
Incruse Ellipta is used to help people with chronic obstructive pulmonary disease (COPD) breathe better. COPD is a long-term lung disease that makes it hard to breathe. This medicine is not for sudden breathing problems or asthma.
Information not available.
Incruse Ellipta works by relaxing the muscles around your airways. This helps to open up your airways so that air can flow into your lungs more easily. It makes it easier to breathe.
- • Upper respiratory infection
- • Headache
- • Back pain
- • Sore throat
- • Sinus infection
- • Lower respiratory tract infection
- • Constipation
- • Diarrhea
- Difficulty breathing 1,869
- Inhaler not working correctly 1,281
- Skipped a dose of medicine 1,017
- Asthma 814
- Chronic obstructive pulmonary disease (COPD) 764
- Dyspnoea 1,352
- Cough 701
- Asthma 604
- Wrong Technique In Device Usage Process 520
- Pneumonia 509
No specific warnings noted.
Incruse Ellipta is not for treating asthma. Do not use Incruse Ellipta if you are allergic to milk proteins or any of the ingredients in the inhaler. Talk to your doctor right away if you have new or worsening eye problems or problems passing urine.
No pregnancy information available.
Not enough information is available to know if Incruse Ellipta is safe to use during pregnancy. Talk to your doctor if you are pregnant or plan to become pregnant.
Also Compare, Nearby Drugs
Compare aclidinium with
Compare umeclidinium with
How to Read This aclidinium vs umeclidinium Comparison
aclidinium is classified in the Long-Acting Muscarinic Antagonist (LAMA) drug class, while umeclidinium sits within the Long-Acting Muscarinic Antagonist (LAMA) class. Because both drugs share the same classification, they are often considered interchangeable in theory, but clinical outcomes rarely track that cleanly. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, aclidinium has 5,745 submissions while umeclidinium has 3,686. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for aclidinium or umeclidinium.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.